
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 7)*

Keenova Therapeutics plc

(Name of Issuer)

Common Stock, par value \$0.01 per share

(Title of Class of Securities)

(CUSIP Number)

James Kasmarcik
Silver Point Capital, L.P., Two Greenwich Plaza, Suite 1
Greenwich, CT, 06830
203-542-4200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/20/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

Name of reporting person

1

Silver Point Capital, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3 SEC use only
Source of funds (See Instructions)

4 OO
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 DELAWARE

Sole Voting Power

7

0.00

Number of Shares Beneficially

Shared Voting Power

Owned by Each Reporting Person

8

6,035,214.00

Sole Dispositive Power

9

0.00

With: Shared Dispositive Power

10

6,035,214.00

Aggregate amount beneficially owned by each reporting person

11 6,035,214.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
Percent of class represented by amount in Row (11)

13 15.2 %

Type of Reporting Person (See Instructions)

14 IA, PN

SCHEDULE 13D

CUSIP No.

Name of reporting person

1 Edward A. Mule

Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 OO
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 UNITED STATES

Number of 7 Sole Voting Power

Shares	
Beneficially	0.00
Owned by	Shared Voting Power
Each	8
Reporting	6,035,214.00
Person	Sole Dispositive Power
With:	9
	0.00
	Shared Dispositive Power
	10
	6,035,214.00
	Aggregate amount beneficially owned by each reporting person
11	6,035,214.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	<input type="checkbox"/>
	Percent of class represented by amount in Row (11)
13	15.2 %
	Type of Reporting Person (See Instructions)
14	IN

SCHEDULE 13D

CUSIP No.

1	Name of reporting person
	Robert J. O'Shea
	Check the appropriate box if a member of a Group (See Instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	SEC use only
	Source of funds (See Instructions)
4	OO
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	<input type="checkbox"/>
	Citizenship or place of organization
6	UNITED STATES
	Sole Voting Power
7	0.00
Number of	Shared Voting Power
Shares	8
Beneficially	6,035,214.00
Owned by	Sole Dispositive Power
Each	9
Reporting	0.00
Person	Shared Dispositive Power
With:	10
	6,035,214.00
11	Aggregate amount beneficially owned by each reporting person

6,035,214.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12



Percent of class represented by amount in Row (11)

13

15.2 %

Type of Reporting Person (See Instructions)

14

IN

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

(a)

Common Stock, par value \$0.01 per share

Name of Issuer:

(b)

Keenova Therapeutics plc

Address of Issuer's Principal Executive Offices:

(c)

College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, IRELAND , D15 TX2V.

Item 1 Comment: This Amendment No. 7 (the "Amendment") amends the statement on Schedule 13D originally filed by the Reporting Persons on November 24, 2023, as amended by Amendment No. 1 filed by the Reporting Persons on January 22, 2024, Amendment No. 2 filed by the Reporting Persons on July 8, 2024, Amendment No. 3 filed by the Reporting Persons on March 18, 2025, Amendment No. 4 filed by the Reporting Persons on November 5, 2025, Amendment No. 5 filed by the Reporting Persons on December 10, 2025, and Amendment No. 6 filed by the Reporting Persons on April 17, 2026 (as amended, the "Schedule 13D"). Capitalized terms used but not otherwise defined in this Amendment shall have the meanings ascribed to such terms in the Schedule 13D. Except as otherwise provided herein, each Item of the Schedule 13D remains unchanged.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Schedule 13D is hereby supplemented as follows: The source of funds used in the acquisitions reported in Item 5 was working capital of the Reporting Persons.

Item 5. Interest in Securities of the Issuer

The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Amendment are incorporated herein by reference. The Reporting Persons currently beneficially own 6,035,214 shares of Common Stock, representing 15.2% of the shares of Common Stock outstanding. As reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026, as of May 5, 2026, there were 39,581,987 shares of Common Stock issued and outstanding.

(a)

The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Amendment are incorporated herein by reference.

(b)

The following sets forth all transactions in the Common Stock effected by the Reporting Persons during the last 60 days: On May 19, 2026, the Reporting Persons purchased 187,500 shares of Common Stock at a price per share of \$90.50 in the open market through brokers. On May 20, 2026, the Reporting Persons purchased 210,000 shares of Common Stock at a price per share of \$90.50 in the open market through brokers.

(c)

Other than as disclosed in Item 4, no person other than the Reporting Persons are known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Common Stock held by the Reporting Persons.

(d)

Not applicable.

(e)

Item 7. Material to be Filed as Exhibits.

Exhibit No. Description 1 Joint Filing Agreement, dated as of May 22, 2026, by and among the Reporting Persons 2 Power of Attorney of Robert J. O'Shea and Edward A. Mule (incorporated here by reference to Schedule 13G filed by Silver Point Capital, L.P., Edward A. Mule and Robert J. O'Shea with the Securities and Exchange Commission on February 16, 2016 relating to TopBuild Corp.)

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Silver Point Capital, L.P.

Signature: /s/ Steven Weiser

Name/Title: Steven Weiser/Authorized Signatory

Date: 05/22/2026

Edward A. Mule

Signature: /s/ Steven Weiser

Name/Title: Steven Weiser/Attorney-in-fact

Date: 05/22/2026

Robert J. O'Shea

Signature: /s/ Steven Weiser

Name/Title: Steven Weiser/Attorney-in-fact

Date: 05/22/2026